Catalogo dei prodotti della ricerca

CHIARETTI, sabina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.958
EU - Europa 2.071
AS - Asia 749
AF - Africa 39
SA - Sud America 39
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.864
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.900
IT - Italia 713
SE - Svezia 616
IN - India 299
CN - Cina 189
DE - Germania 162
FI - Finlandia 161
UA - Ucraina 113
PK - Pakistan 93
GB - Regno Unito 72
RO - Romania 69
SG - Singapore 67
BG - Bulgaria 62
CA - Canada 52
AR - Argentina 34
IE - Irlanda 26
TG - Togo 22
IR - Iran 19
FR - Francia 16
IQ - Iraq 16
BE - Belgio 12
GR - Grecia 12
JP - Giappone 11
ES - Italia 8
ID - Indonesia 7
NL - Olanda 7
AU - Australia 6
EG - Egitto 6
MX - Messico 6
PH - Filippine 6
QA - Qatar 6
TR - Turchia 6
TW - Taiwan 6
AT - Austria 5
CH - Svizzera 5
YE - Yemen 5
ZA - Sudafrica 5
HK - Hong Kong 4
KZ - Kazakistan 4
NG - Nigeria 4
RU - Federazione Russa 4
BR - Brasile 3
AZ - Azerbaigian 2
EC - Ecuador 2
EE - Estonia 2
KR - Corea 2
MY - Malesia 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
BT - Bhutan 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
EU - Europa 1
HR - Croazia 1
IL - Israele 1
LI - Liechtenstein 1
MK - Macedonia 1
MU - Mauritius 1
NO - Norvegia 1
SC - Seychelles 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.864
Salva come PNG Salva come JPEG
Città #
Fairfield 1.008
Ashburn 465
Chandler 437
Seattle 407
Woodbridge 401
Houston 350
Wilmington 341
Cambridge 316
Rome 278
Ann Arbor 222
Princeton 185
Dearborn 171
Plano 134
San Paolo di Civitate 125
Bremen 102
Lawrence 99
Boston 94
Millbury 75
San Diego 72
Beijing 66
Sofia 61
Faisalabad 55
Des Moines 53
Andover 51
New York 49
Jacksonville 42
Helsinki 39
Sargodha 38
Dublin 25
Federal 24
Toronto 24
Boardman 22
Lomé 22
Norwalk 22
Milan 21
Florence 20
Hefei 20
Southend 20
Falls Church 18
Chieuti 17
San Mateo 17
Singapore 17
Nanjing 16
Ottawa 16
Bühl 14
Los Angeles 12
Giussano 11
Kunming 10
Phoenix 10
Brussels 9
Buenos Aires 9
Fremont 9
London 8
Nanchang 8
Qazvin 8
Guangzhou 7
Doha 6
Mexico City 6
Naples 6
Redmond 6
Shenyang 6
Bologna 5
Chicago 5
Denver 5
Mumbai 5
Redwood City 5
Sanaa 5
Vienna 5
Wuhan 5
Bengaluru 4
Davao City 4
Indiana 4
Istanbul 4
Kirkuk 4
Kurdistan 4
Melbourne 4
Paris 4
Pune 4
Al Mansurah 3
Baghdad 3
Bari 3
Bene Vagienna 3
Bucharest 3
Buffalo 3
Cagliari 3
Capua 3
Central 3
Chongqing 3
Council Bluffs 3
Derby 3
Edinburgh 3
Erbil 3
Fuzhou 3
Genoa 3
Grafing 3
Hounslow 3
Hsinchu County 3
Lagos 3
Livorno 3
Lyon 3
Totale 6.344
Salva come PNG Salva come JPEG
Nome #
New approaches to the management of adult acute lymphoblastic leukemia 304
An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase 106
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). 104
The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPalpha 102
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimale residual disease-oriented GIMEMA LAL1913 102
Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. 96
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia 95
Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia 94
Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adults 90
Critical role of c-Myc in acute myeloid leukemia involving direct regulation of miR-26a and histone methyltransferase EZH2 90
A case of late isolated ovarian relapse of acute lymphoblastic leukemia after an allogeneic stem cell transplant. 89
A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients. Final results of the GIMEMA LAL1509 protocol 87
Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes 84
Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223 83
Spontaneous regression of chronic lymphocytic leukemia: Clinical and biologic features of 9 cases 81
Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival 80
The epigenetic factor BORIS/CTCFL regulates the NOTCH3 gene expression in cancer cells. 80
Functional analysis and gene expression profile of umbilical cord blood regulatory T cells 80
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. 79
ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression 79
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. 78
Atypical chronic myeloid leukemia in a patient with aplastic anemia 78
Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. 77
Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. 77
Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance 76
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia 76
Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. 76
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 76
A mammalian microRNA expression atlas based on small RNA library sequencing 75
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia 75
Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes. 74
BCR-ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells. 74
B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures 74
The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells 73
Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia 73
Angiogenic activity in 1(g)V(H) mutated and unmutated chronic lymphocytic leukemia (CLL): Indications for the therapeutic use of VEGF-signaling inhibitors. 72
A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis. 72
Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease. 70
Protein Kinase Gene Expression Profiling and In Vitro Functional Experiments Identify Novel Potential Therapeutic Targets in Adult Acute Lymphoblastic Leukemia 69
T-cell acute lymphoblastic leukemia. 69
Whole-genome amplification for the detection of molecular targets and minimal residual disease monitoring in acute lymphoblastic leukaemia 68
SQSTM1-NUP214: a new gene fusion in adult T-cell acute lymphoblastic leukemia 68
null 68
TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poorresponse to induction therapy. 67
AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile 67
A broad and integrated diagnostic work-up for a modern management of acute lymphoblastic leukemia (ALL) 66
Genomic Characterization of Acute Leukemias. 66
Bayesian error-in-variable survival model for the analysis of GeneChip arrays. 66
ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon 66
Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis 65
RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications 65
Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances 65
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia 65
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness 64
Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis. 64
ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 re-arrangement and the pre-B stage of differentiation, and prognostic implications. 64
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial 64
IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells 63
Characterization of B- and T-Lineage Acute Lymphoblastic Leukemia by Integrated Analysis of MicroRNA and mRNA Expression Profiles 63
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. 63
DROPLET DIGITAL PCR DETECTION OF THE T315I BCR::ABL1 KD MUTATION IN ADULT PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 62
Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations 62
null 62
NOTCH1 mutations in+12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of+12 CLL 62
null 60
Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors 60
Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation 58
null 58
null 58
The changing scene of adult acute lymphoblastic leukemia 57
null 57
IgV(H) germline and mutated chronic lymphocytic leukemia (CLL) cases exert a diverse responsiveness upon BCR ligation. 56
Myeloid/T-cell acute lymphoblastic leukemia in children and adults. 56
null 56
NOTCH1, SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment 55
null 54
null 54
null 54
null 53
A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome. 53
null 53
Gene expression profile reveals a unique pattern of protein kinases in chronic lymphocytic leukemia (CLL) potential role of the second generation protein kinase inhibitors 52
null 52
Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML). 51
null 51
The microRNA (miR) profile in B-cell chronic lymphocytic leukemia (CLL) reveals a differential expression of miR-21, miR-155 and miR-150 between leukemic and normal B lymphocytes, and of miR-150, miR-29bc and miR-223 between IgV(H) mutated and unmutated patients 50
Gene expression profile of protein kinases reveals a distinctive signature of chronic lymphocytic leukemia (CLL) and points to a role of second generation protein kinase inhibitors. 50
null 50
null 49
New Approaches to the Management of Adult Acute Lymphoblastic Leukemia 49
Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. 48
EVALUATION OF TP53 MUTATIONS WITH THE AMPLICHIP P53 ARRAY IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): HIGHER SENSITIVITY AND CORRELATION WITH CLINICAL OUTCOME 47
IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: A GIMEMA AL WP report 47
Anti-leukemic activity of the novel MEK inhibitor PD0325901 47
null 47
A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome. 47
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells 47
Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling. 47
Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia 46
ATM Gene Alterations in CLL Patients Induce Gene Profile Clusters and Predict Disease Progression 45
Totale 6.918
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.514
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.514
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019659 0 0 0 0 0 0 0 0 0 0 355 304
2019/20202.117 270 67 16 90 224 366 321 252 232 121 69 89
2020/2021631 80 88 42 40 17 14 9 80 82 98 68 13
2021/20222.024 21 97 143 257 230 45 42 152 168 155 365 349
2022/20231.953 356 385 119 227 163 232 33 151 148 18 75 46
2023/20241.065 58 150 57 102 93 202 68 187 32 113 3 0
Totale 9.260